Abstract

PurposeWe systematically reviewed the effects of NIV for acute respiratory failure (ARF) in low- and low-middle income countries. Materials and methodsWe searched MEDLINE, CENTRAL, and EMBASE (to January 2016) for observational studies and trials of NIV for ARF or in the peri-extubation period in adults and post-neonatal children. We abstracted outcomes data and assessed quality. Meta-analyses used random-effect models. ResultsFifty-four studies (ten pediatric/n=1099; 44 adult/n=2904), mostly South Asian, were included. Common diagnoses were pneumonia and chronic obstructive pulmonary disease (COPD). Considering observational studies and the NIV arm of trials, NIV was associated with moderate risks of mortality (pooled risk 9.5%, 95% confidence interval (CI) 4.6–14.5% in children; 16.2% [11.2–21.2%] in adults); NIV failure (10.5% [4.6–16.5%] in children; 28.5% [22.4–34.6%] in adults); and intubation (5.3% [0.8–9.7%] in children; 28.8% [21.9–35.8%] in adults). The risk of mortality was greater (p=0.035) in adults with hypoxemic (25.7% [15.2–36.1%]) vs. hypercapneic (12.8% [7.0–18.6%]) ARF. NIV reduced mortality in COPD (relative risk [RR] 0.47 [0.27–0.79]) and in patients weaning from ventilation (RR 0.48 [0.28–0.80]). The pooled pneumothorax risk was 2.4% (0.8–3.9%) in children and 5.2% (1.0–9.4%) in adults. Meta-analyses had high heterogeneity. ConclusionsNIV for ARF in these settings appears to be effective.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.